Journal profile · ENDOCRINOLOGY & METABOLISM
Expert Review of Endocrinology & Metabolism
ISSN 1744-6651 · eISSN 1744-8417 · Taylor & Francis
Expert Review of Endocrinology & Metabolism: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 2.9 (journal website); subscription journal; APC charged, amount not published; median 110 days to acceptance (96 articles, last 24 months); acceptance rate 23% (journal website); 61 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Expert Review of Endocrinology & Metabolism is published by Taylor & Francis and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Diabetes Treatment and Management, Pituitary Gland Disorders and Treatments and Growth Hormone and Insulin-like Growth Factors, together about 21.9% of its articles. Its main subfields are Endocrinology, Diabetes and Metabolism. (generated from OpenAlex topic counts and CAS ranking data)
Expert Review of Endocrinology & Metabolism [ISSN 1744-6651]; [e-ISSN 1744-8417] is a MEDLINE-indexed, peer-reviewed journal providing extensive coverage of state-of-the-art research and clinical advancements in endocrine control and metabolism. The journal is an essential contribution to decision-making for disorders of endocrinology and metabolism for all professionals within this specialty, encompassing the most stimulating and up-to-date topics in clinical diseases such as: diabetes, obesity, osteoporosis, thyroid disease, adrenal insufficiency and pituitary tumors, as well as disorders associated with growth, reproduction, weight management and hormone-regulated gene expression. The journal focuses on the following key areas: Screening, prevention and diagnostics Existing and novel therapeutics Related molecular genetics Pathophysiology Epidemiology The journal welcomes clinically focused original research, reviews, editorials and drug profile articles. Please note that the journal does not accept case reports or case series and does not accept papers focused on pre-clinical work and/or animal studies. Once your paper has been assessed for suitability by the Editorial Team, it will then be double-anonymous peer-reviewed by independent, expert referees. Reach an international clinical and medical audience alongside other key opinion leaders in your field by publishing with Expert Review of Endocrinology & Metabolism, part of the Expert Collection brand. Authors can choose to publish gold open access in this journal and may choose to publish using our Accelerated Publication services. For any pre-submission enquiries, please contact the Commissioning Editor.
From the journal's Aims & Scope
Research area (LetPub): ENDOCRINOLOGY & METABOLISM
Editor-in-chief Thomas BarberPublisher website
Editorial board by country: none in mainland China; most named United Kingdom 2, Sweden 1 (3 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Diabetes Treatment and ManagementMedicine8.6%
- Pituitary Gland Disorders and TreatmentsMedicine6.9%
- Growth Hormone and Insulin-like Growth FactorsMedicine6.4%
- Pancreatic function and diabetesMedicine6%
- Diabetes Management and ResearchMedicine5.5%
- Metabolism, Diabetes, and CancerBiochemistry, Genetics and Molecular Biology5.3%
- Thyroid Cancer Diagnosis and TreatmentMedicine5.2%
- Diet and metabolism studiesMedicine4.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Endocrinology & Metabolism | Zone 3 |
Top journal: noReview journal: yes
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Endocrinology & Metabolism | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
JCR / CiteScore quartiles on the journal's website
- CiteScore Q2 · 2025
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
ESCIScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEPubMedEmbaseCASPublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher) 2025
- 2.9Publisher website ·
- 5-year impact factor (publisher) 2025
- 3.1Publisher website ·
- CiteScore 2026-06
- 5.5LetPub ·
- CiteScore (publisher) 2025
- 5.5Publisher website ·
- SJR 2026-06
- 1.11LetPub ·
- SJR (publisher) 2025
- 1.11Publisher website ·
- SNIP 2026-06
- 0.9LetPub ·
- SNIP (publisher) 2025
- 0.9Publisher website ·
- h-index
- 48OpenAlex ·
- i10-index
- 363OpenAlex ·
- 2-year mean citedness
- 3.47OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 2.08%LetPub ·
Volume
- Articles per year
- 52LetPub ·
- Downloads per year (publisher)
- 129,000Publisher website ·
Articles by year OpenAlex count · 1,293 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 30 | 17 | 7 |
| 2025 | 61 | 20 | 196 |
| 2024 | 40 | 18 | 251 |
| 2023 | 65 | 19 | 574 |
| 2022 | 45 | 14 | 625 |
| 2021 | 36 | 12 | 641 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
110 daysMedian, submission to acceptance · P25–P75 77 days – 143 days
- Acceptance to online
- median 13 days (96 articles)
- Submission to online
- median 132 days
- Sample
- 96 articles with submission and acceptance dates (97 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Acceptance rate (publisher)
- 23%Publisher website ·
- Submission to first decision
- 3 daysPublisher website ·
- First decision after review
- 64 daysPublisher website ·
- Acceptance to publication
- 15 daysPublisher website ·
- Peer review
- Double anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Subscription journalLetPub
A subscription journal: articles are read by subscription or purchase, and authors usually pay no publication charge.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| Publisher website | Yes, amount not published | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare1 items from the author guidelines
- Not considered
- case reports; case series; papers focused on pre-clinical work; animal studies
Article types accepted4
- drug profileThe journal welcomes clinically focused original research, reviews, editorials and drug profile articles.Length not stated
- editorialThe journal welcomes clinically focused original research, reviews, editorials and drug profile articles.Length not stated
- original researchThe journal welcomes clinically focused original research, reviews, editorials and drug profile articles.Length not stated
- reviewThe journal welcomes clinically focused original research, reviews, editorials and drug profile articles.Length not stated
Policy excerpts from the journal's websiteOpen access, Peer review
- Open access Open access
Expert Review of Endocrinology & Metabolism is a hybrid open access journal that is part of the Taylor & Francis Open Select publishing program, giving you the option to publish open access. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research. Why choose open access? Increase the…
Source ↗Publisher website ·- Peer review
The journal does not accept case reports or case series and does not accept papers focused on pre-clinical work and/or animal studies. Model summary
Please note that the journal does not accept case reports or case series and does not accept papers focused on pre-clinical work and/or animal studies.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Taylor & Francis
- ISSN
- 1744-6651
- Electronic ISSN
- 1744-8417
- Latest issue on the website
- Volume 21, Issue 5 (2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
FAQ
Frequently asked questions about Expert Review of Endocrinology & Metabolism
What CAS zone is Expert Review of Endocrinology & Metabolism in?
In the 2025 upgraded edition of the CAS Journal Ranking, Expert Review of Endocrinology & Metabolism is in Zone 3 of Medicine, and in Zone 3 of the minor category Endocrinology & Metabolism. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Expert Review of Endocrinology & Metabolism?
The journal's website gives an impact factor of 2.9 (2025); this is the journal's own figure, as LetPub lists none for it; CiteScore 5.5, h-index 48.
How long does peer review take at Expert Review of Endocrinology & Metabolism?
Based on the dates recorded on 96 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 110 days (interquartile range 77–143 days); the journal's website gives an acceptance rate of 23%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Expert Review of Endocrinology & Metabolism based?
Of the 3 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United Kingdom (2) and Sweden (1). Counted from the institutions listed on the board page; for reference only.
Which databases index Expert Review of Endocrinology & Metabolism?
According to LetPub and DOAJ records, Expert Review of Endocrinology & Metabolism is indexed in ESCI and Scopus. The journal's website also lists MEDLINE, PubMed, Embase and CAS; that list has not been checked against each database.
Is Expert Review of Endocrinology & Metabolism open access, and what is the APC?
Expert Review of Endocrinology & Metabolism is a subscription journal. APC charged, amount not published.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .